Evidence map›Paper›PMID 42699146›Full record

ArticleESMO real world data and digital oncology2026

Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE).

H Abdallah, Y Owoseni, B Baraka, A Ghose, Konstantis, R Muhammad, A Maniam, N Atsumi, S Horne, A Nazir and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

H AbdallahOncology Department, University Hospitals of Leicester NHS Trust, Leicester, UK.
Y OwoseniOncology Department, University Hospitals of Leicester NHS Trust, Leicester, UK.
B BarakaOncology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK.
A GhoseOncology Department, Barts Cancer Centre, Barts Health NHS Trust, London, UK.
KonstantisOncology Department, Princess Alexandra Hospital NHS Trust, Harlow, UK.
R MuhammadOncology Department, Princess Alexandra Hospital NHS Trust, Harlow, UK.
A ManiamOncology Department, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
N AtsumiOncology Department, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
S HorneOncology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
A NazirOncology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
L MooneyOncology Department, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, UK.
F NazeerOncology Department, Royal Surrey Cancer Centre, Royal Surrey NHS Foundation Trust, Surrey, UK.
L McAvanOncology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
M AbrahamOncology Department, Dorset Cancer Centre, University Hospitals Dorset NHS Foundation Trust, Poole, UK.
E BeanOncology Department, Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
D MorganOncology Department, Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, UK.
G LangfordOncology Department, Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, UK.
E MorrisOncology Department, University College London Hospitals NHS Foundation Trust, London, UK.
E DanielsOncology Department, Dyson Cancer Centre, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.
R PravinkumarOncology Department, Edinburgh Cancer Centre, Edinburgh, UK.
S MohammedOncology Department, Great Western Hospitals NHS Foundation Trust, Swindon, UK.
S RazaOncology Department, Hull University Teaching Hospitals NHS Trust, Cottingham, UK.
C BlairOncology Department, University Hospitals of Bristol and Weston NHS Trust, Bristol, UK.
R KhanOncology Department, The Christie NHS Foundation Trust, Manchester, UK.
M TsalicOncology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
R KussaibatiOncology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
R DouglasOncology Department, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, UK.
K PanagiotisOncology Department, Frimley Health NHS Foundation Trust, Camberley, UK.
S WatersOncology Department, Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, UK.
J SmithOncology Department, Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
E PapadimitrakiOncology Department, University College London Hospitals NHS Foundation Trust, London, UK.
C MichieOncology Department, Edinburgh Cancer Centre, Edinburgh, UK.
C WilsonOncology Department, The Christie NHS Foundation Trust, Manchester, UK.
O AyodeleOncology Department, University Hospitals of Leicester NHS Trust, Leicester, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Abemaciclib plus endocrine therapy improves outcomes in high-risk hormone receptor-positive, HER2-negative early breast cancer (EBC) in monarchE, but real-world tolerability, dose modification, and treatment persistence in routine UK practice remain incompletely characterised. Patients and methods: A retrospective, multicentre study across 21 NHS Trusts of adults with high-risk EBC initiating adjuvant abemaciclib. The primary endpoint was treatment duration, whereas secondary endpoints included dose modifications, discontinuations, and toxicity profiles. Results: The cohort comprised 1026 patients (median age 54 years, range 22-87); 82.9% were Caucasian. Median abemaciclib duration was 15.5 months (range 0.2-24), 25.3% completed 24 months, and 54.9% remained on treatment at data cut-off. Overall, 19.7% discontinued abemaciclib, most commonly due to toxicity (15.9%), and 3.8% discontinued for disease progression. Dose modifications were frequent: 64.6% required ≥1 dose reduction, and 25.2% required ≥2 reductions. Common adverse events were diarrhoea (76.4%, grade ≥3 5.8%), neutropenia (43.4%, grade ≥3 8.2%), anaemia (33.2%, grade ≥3 0.3%), and transaminitis (17.2%, grade ≥3 1.8%). Acute kidney injury occurred in 21.6% (grade ≥3 0.4%), including one fatal case. Increasing diarrhoea and neutropenia grades were associated with first dose reduction; in multivariable analyses, grade ≥3 diarrhoea [adjusted odds ratio (OR) 7.62, 95% confidence interval (CI) 3.44-16.87, Conclusions: Although abemaciclib tolerability and discontinuation rates align with trial data, dose reductions are substantially more frequent in routine practice. Proactive toxicity management is vital to sustain treatment exposure, but longer follow-up is needed to establish how these reductions affect overall efficacy.

Indexed as

abemaciclibadjuvantCONCISEearly breast cancerreal-world-evidence

Identifiers

PMID42699146
PMCPMC13543962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.